Innovation Pharmaceuticals Inc (IPIX)

[CallMeCrazy]

Great article! The Impatient Should Also Take Note

Although there are still steps to be completed before the application can be performed in patients on a large scale, such results inspire the researchers to continue investigating the uses of brilacidin in various models to combat other species of fungi. “The process is long, but it is important to put the name of Brazil on the science map, to show that we, from universities in the Northeast, can contribute with value to research and publish articles in high impact journals such as those of the Nature group,” reinforces the professor.

https://ufrn.br/en/press/features-and-knowledge/69808/nova-arma-contra-os-fungos

IMO, the "long" process equates to a "long" opportunity for share acquisition.

Message in reply to:

What does Merck think of this?
https://ufrn.br/en/press/features-and-knowledge/69808/nova-arma-contra-os-fungos
"One of the problems with treating mycoses is that there are basically only three groups of drugs used to treat serious diseases. The first and possibly best known by the population is the group named “azol”, a suffix present in many ointments and medicines that fight infections of this nature. The issue that hinders their effectiveness is that, because it is used in similar compounds to treat plant diseases, especially in agriculture, the patient can be infected by a resistant fungus that was selected in the environment when it came into contact with these fungicides.
The second is amphotericin B, a drug available only in hospitals and that presents a high level of toxicity to the patient’s kidneys, which limits its use. The third is the echinocandins, a drug represented by caspofungin – present in the study -, whose disadvantage is concentrated in the fact that the drug does not kill the fungus, but only prevents its growth. Because the fungus mainly infects people with weakened bodies, the patient’s immune system is not always able to fully act and eliminate it, so it can occasionally regrow.
The results noted in the paper indicate that combinations of BRI and clinically used antifungal drugs, such as caspofungin, improve the outcome of the treatment of aspergillosis and other fungal infections. “It can’t kill the fungus alone in vitro, but when I put it together with caspofungin, it potentiates its effect; with brilacidin, it kills the fungus. From the treatment point of view, this is very interesting,” explains Rafael Bastos.

The study has also tested the drug alone and in combination with caspofungin in mice and proved that, in vivo, it acts against the fungus both when administered alone and together with other drugs. This happens against infection in the lungs (pulmonary aspergillosis) as well as in the eyes (fungal keratitis).

In addition to Aspergillus fumigatus, brilacidin alone or in combination with caspofungin kills Cryptococcus (causing cryptococcosis), Candida albicans (causing candidiasis) and even the recently discovered super fungus, Candida auris. Cryptococcus is a fungus that is naturally resistant to caspofungin, but when it faces it together with brilacidin, it becomes sensitive."